SIGA Technologies, Inc. (OTCMKTS:SIGA) shares traded up 5.9% on Friday . The company traded as high as $4.91 and last traded at $4.85, 198,436 shares changed hands during trading. An increase of 13% from the average session volume of 174,853 shares. The stock had previously closed at $4.58.

The stock’s 50 day simple moving average is $4.99 and its two-hundred day simple moving average is $5.14.

In other news, Director Paul G. Savas bought 20,000 shares of SIGA Technologies stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $4.34 per share, for a total transaction of $86,800.00. Also, CEO Phillip Louis Gomez III bought 10,000 shares of SIGA Technologies stock in a transaction dated Monday, December 9th. The stock was purchased at an average price of $4.34 per share, for a total transaction of $43,400.00. Insiders bought a total of 35,000 shares of company stock worth $151,900 in the last 90 days. 4.71% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC acquired a new position in SIGA Technologies during the 3rd quarter worth about $46,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in SIGA Technologies during the 4th quarter worth about $47,000. Bowling Portfolio Management LLC acquired a new position in SIGA Technologies during the 4th quarter worth about $50,000. Investment Management of Virginia LLC acquired a new position in SIGA Technologies during the 3rd quarter worth about $52,000. Finally, SG Americas Securities LLC bought a new stake in SIGA Technologies during the 4th quarter worth about $55,000. Institutional investors and hedge funds own 6.66% of the company’s stock.

About SIGA Technologies (OTCMKTS:SIGA)

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Recommended Story: 52-Week High/Low Prices For Stock Selection

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.